NCT03432793已完成1 期
A Phase 1, Fixed-Sequence, Open-Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD-9855 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamine
研究概览
简要总结
This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Willing and able to give written, signed informed consent
- •Male subjects 19 to 55 years of age (inclusive)
- •Body mass index 19 to 32 kg/m2 (inclusive), and weigh at least 55 kg
- •No clinically important abnormal physical findings as determined by the Principal Investigator (PI) at the screening and Day -1 examinations
- •Negative for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) antibody at screening.
- •No clinically important laboratory abnormalities as determined by the PI
- •Ability to communicate effectively with the Investigator and to comply with all study requirements, restrictions, and direction of the clinic staff
- •Male subjects must abstain from sexual intercourse or use a highly effective method of birth control
- •Male smokers: Subjects who self-report to have smoked > 9 cigarettes per day for at least 6 month prior to screening as confirmed by urine cotinine test at screening and Day -
- •Male smokers: Subjects must be willing to continue consistent use of their tobacco products throughout the study.
- •Additional inclusion criteria apply
排除标准
- •Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) antibody at screening.
- •History or presence of clinically significant respiratory, gastrointestinal, renal, hepatic, hematologic, neurologic (including history of seizure and insomnia), cardiovascular (including postural orthostatic hypotension or tachycardia), psychiatric (including depression and known addictive disorders), musculoskeletal, genitourinary (including urinary retention), immunologic, or dermatologic disorder.
- •Any other condition that, in the opinion of the PI, would confound or interfere with study participation; evaluation of safety, tolerability, or PK of the investigational drug; or prevent compliance with the study protocol
- •Any history of suicide attempts/ideation or current suicidal ideation.
- •Have participated in another clinical trial of an investigational drug (or medical device) within 30 days (or 5 half-lives of the investigational drug if longer than 30 days) prior to Screening, or are currently participating in another trial of an investigational drug (or medical device), or intending to participate in another trial of an investigational drug (or medical device) before completion of all scheduled safety evaluations in this trial
- •Additional inclusion criteria apply
研究组 & 干预措施
TD-9855 + Fluvoxamine + Caffeine
Experimental
Male smokers will receive TD-9855, fluvoxamine, and caffeine
干预措施: TD-9855 (Drug)
TD-9855 + Fluvoxamine + Caffeine
Experimental
Male smokers will receive TD-9855, fluvoxamine, and caffeine
干预措施: Fluvoxamine (Drug)
TD-9855 + Fluvoxamine + Caffeine
Experimental
Male smokers will receive TD-9855, fluvoxamine, and caffeine
干预措施: Caffeine (Drug)
TD-9855 + Itraconazole + Caffeine
Experimental
Male non-smokers will receive TD-9855, itraconazole, and caffeine
干预措施: TD-9855 (Drug)
TD-9855 + Itraconazole + Caffeine
Experimental
Male non-smokers will receive TD-9855, itraconazole, and caffeine
干预措施: Itraconazole (Drug)
TD-9855 + Itraconazole + Caffeine
Experimental
Male non-smokers will receive TD-9855, itraconazole, and caffeine
干预措施: Caffeine (Drug)
结局指标
主要结局
Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamine
时间窗: Day 9 and Day 24
次要结局
- Correlation between caffeine PK disposition and TD-9855 plasma exposure(Day 9 and Day 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy SubjectsDrug Drug InteractionNCT06232109Asceneuron S.A.50
已完成
1 期
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With MigraineMigraineNCT04179474Allergan40
已完成
1 期
Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male VolunteersHealthyPharmacokinetics of QuetiapineNCT01908296Astellas Pharma Inc24
已完成
1 期
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPIRelapsed or Refractory LymphomaNCT05602597Hutchmed59
已完成
1 期
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.HealthyNAFLDNCT04845646Gannex Pharma Co., Ltd.24